clinical trial · NCT05438043
A Study of Daratumumab
Janssen Research & Development, LLC·phase3·recruiting·n = 500
Multiple MyelomaDaratumumabCarfilzomibDexamethasoneLenalidomidePomalidomide
brief summary
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.
started
Dec 15, 2022
primary completion
Jan 31, 2029
completion
Jan 31, 2029
last updated
Apr 13, 2026
official title
A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol